IFNB1 and neoplasm: Combining cAT-MSC-IFN-β with cisplatin produced a significantly greater tumor growth inhibition compared to cisplatin alone (p<0.001), cAT-MSC-Mock (p<0.001) or cAT-MSC-IFN-β alone (p<0.05).